Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)

Market Cap	4.85B -28.7%
Revenue (ttm)	1.00B -14.4%
Net Income	235.05M -32.0%
EPS	0.22 -32.0%
Shares Out	1.05B
PE Ratio	20.65
Forward PE	n/a
Dividend	0.20 (4.31%)
Ex-Dividend Date	May 29, 2026

Volume	10,547,230
Open	4.850
Previous Close	4.750
Day's Range	4.630 - 4.850
52-Week Range	4.020 - 6.770
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHE:300039

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,197
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300039

Financial Performance

In 2025, SHE:300039's revenue was 1.15 billion, a decrease of -21.76% compared to the previous year's 1.47 billion. Earnings were 278.58 million, a decrease of -25.83%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error